In-house pancreatic cancer cell lines studied for cytokine secretion:  HPAC, Patu8988T, Panc-1, Paca-2, Panc-10.05, Patu8902, L3.6PL, HPAFII, PL-45, Capan1. Cytokines VEGF, IL-8, IL-1alpha, INFalpha2, IL-15 by Luminex. Conditioned media sampled at 6, 10 and 13 days after plating. 

Please fill out a form or call our sales line to discuss your preclinical needs:

​1-617-513-5280


Or send an email directly to cgebert {at} woodlandpharma.com

The standard model runs for 9wks on HFD, with incidence of dysplasia leading to hepatocellular carcinoma (HCC) evident after 12wks of HFD.

3D Cultures, in vitro

- Inhibition of tumor growth

- Inhibition of dispersal / spreading

​- Inhibition of invasion

- Radiation biology - protection and
   sensitization assays are available

Highlighted Orthotopic Model:  4T1 Breast Cancer for Immuno-oncology and Metastasis Studies

"The 4T1 mammary carcinoma is a transplantable tumor cell line that is highly tumorigenic and invasive and, unlike most tumor models, can spontaneously metastasize from the primary tumor in the mammary gland to multiple distant sites including lymph nodes, blood, liver, lung, brain, and bone."  from  Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model.  2001.   Woodland has validated this 4T1 model for lung metastasis.  

Other Liver Injury Models:

- CCl4

- Thioacetamide

Please ask us about pancreatitis models.  We seek a co-developer to support optimization, validation and characterization of a diet+chemical insult-driven pancreatitis model of our own design.  We will adopt the academically developed cerulein pancreatitis model for a first customer willing to support the model validation, based on published protocols.

Liver disease is a progressive diseasewith multiple pathways to inflammatory damage.  Disease intervention points exists in early, fatty liver stage with steatosis / liver lipids modulators, mid-stage where inflammatory processes are injuring the liver exemplified by cytokine perturbances and liver injury markers (AST/ALT) and late-stage disease in which the stellate cell activation and involvement of MMPs and TIMPs are remodeling the liver. Test your hypothesis in our model.

​​​Woodland is optimizing a third-hit protocol able to induce fibros is in female mice, an industry exclusive.  Other female "NASH" models reported in literature are merely steatosis models, lacking fibrotic pathology.   Please inquire.

Diet-driven Mouse Models of Liver Disease:

- Diet-induced obesity (DIO)

- Steatosis

- NASH/NAFLD



Cell lines compatible with immune-competent mice (C57black6 and Balb/c).

About Woodland Biosciences


​Founder, President & CSO

Mike Briggs, PhD

Mike Briggs has a long career in small molecule discovery and development. In the past few years, Mike was pivotal in establishing the early primary human tumor banks in China, and his thoughts on the discrepancy between tumors that kill and tumors that find their way into tumor banks evolved into Woodland. Mike spent 8 years as the Senior Director of Biology at Vertex, and before that he was a Director and Head of Functional Genomics at the Pfizer/Pharmacia St. Louis site and also directed groups at SmithKline Beecham and Ligand Pharmaceuticals. Mike did his postdoctoral fellowship with the Nobel Laureates Drs. Michael Brown and Joseph Goldstein at the University of Texas Southwestern Medical Center where he and a team co-led by Dr. Xiaodong Wang discovered the sterol regulatory element binding proteins that control LDL receptor modulation of cholesterol in animals and man.  Mike was an EMBO Fellow in Switzerland in the Hafen Lab, a PhD student with Dr. Robert Tjian, Professor of Biochemistry at UC Berkeley and obtained his BA in Biology from the University of Delaware.​ He has more than 40 peer-reviewed articles, book chapters and 4 US patents.


Co-founder of Woodland, VP In Vitro Biology
Raphael Nir, PhD

Dr. Nir is an entrepreneur and scientist with over 25 years of experience commercializing biological production, cell-based assays and biomarkers analysis. He received his BS (Chemistry; 1982), MS (Biochemistry ; 1984) and PhD from Tel-Aviv University (Biotechnology; 1990) and Master in Management (1997; NJIT). Raphael spent 7 years at Schering-Plough in the biotechnology process development group. Since 1997, Dr. Nir has served as the president and CSO of SBH Sciences where he manages all of the company’s R&D activities.  Dr. Nir is also the Co-Founder of another 4 biotech companies including Karyopharm Therapeutics, Galectin Sciences, SBH Diagnostics, and Alma Bio Therapeutics.


Director of Laboratory Operations:

Nikole Siegmund B.S., LAT
Nikole Siegmund is our lab point person managing the day-to-day activities of our busy lab with more than 10 studies ongoing at any given time.  She is LAT-certified by AALAS and has over 12 years experience at Charles River Laboratories with her last position being a Team Leader for research.  Along with her team of key lab people, there is over 60 years of CRO and pharmaceutical company experience in our laboratory staff. While almost all of our studies are in mice and rats, the team has extensive experience in large animal studies including dog and monkey.  


Co-founder & Director of Business Development: 
Carol Gebert, PhD
Carol Gebert has made a career on the business side of biopharma. Carol has held sales, marketing and business development positions at a number of CROs serving discovery and development, including Analytical Biochemistry Labs, Optivia and Cyprotex/Apredica. Carol also sold instrumentation for Thermo/Cellomics and some other instrumentation companies. Carol has a BE in Chemical Engineering from Sydney University and a PhD from the University of NSW, Australia. At Woodland, Carol is responsible for customers, marketing, partnering and funding, including ghost writing of many items sent out under the Woodland name.  Contact Carol at cgebert {at} woodlandpharma.com

​​​Services - Metabolic diseases: Obesity, Fatty Liver Disease and NASH


Mouse male NASH model:  Following industry standard protocols, Woodland establishes liver disease in male mice with an acute chemical insult in neonatal pups followed by chronic insult to the liver by adding a high fat, high fructose diet (HFD) selected to give enhanced steatosis and inflammation.  Ultimately, stellate cell/myofibroblast activation and immune infiltration leads to tissue injury and repair, resulting in the collagen deposition characteristic of NASH.

Highlighted Cancer Cell Line:  MHCC97H for Aggressive HCC and Metastasis Studies

MHCC97H is a highly metastatic hepatocellular carcinoma derived from a chinese patient.  It is useful for HCC flank or orthotopic xenografts, and also flank to liver metastasis studies, with Woodland studies shown here.  The black arrow shows the metastatic colony in a liver histology slide while the red arrow shows a blood vessel. The cell line grows aggressively in vivo, with a typical Woodland growth curve of MHCC97H shown here.  Academic literature supports MHCC97H as useful for in vitro invasion assays.

*Digital image analyses by Reveal Biosciences www.revealbiosciences.com

Click here to jump to oncology service details below

Woodland News & Events (Go to PR page)


April 2017
Woodland announces award of STTR phase 1 grant from NCI with co-applicant Dr. Dan Duda of MGH to capture, bank and characterize HCC tumors in Boston from American liver cancer patients.
 (read full press release here) 


January 2017
Michael Briggs, PhD, President & CSO of Woodland has been appointed to the
Scientific Advisory Board at VetONCOrx.  


September 2016

Michael Briggs, PhD, President & CSO of Woodland has been appointed to the Board of Directors ofCalista Therapeutics. Dr. Briggs has also joined the Scientific Advisory Board of iMetabolic Biopharma.



May 2016

Catabasis Pharmaceuticals presented a poster for a NASH therapy at Digestive Disease Week in San Diego for work done with Woodland. (Link to Catabasis press release)


September 2015 

Dr. Briggs, Woodland Biosciences President & CSO, co-authors article published in Journal of Translational Medicine.  Title: "Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma"  (link)

Woodland Biosciences Preclinical Services is a contract research organization (CRO) offering in vivo services for the study of metabolic diseases and oncology.  We are located in Massachusetts, Boston metrowest, with laboratories at the Tufts Veterinary School in Grafton.

Woodland Biosciences, 200 Westboro Rd., Bldg 21, N. Grafton, MA 01536


NASH/Fibrosis/Fatty Liver DIsease

Woodland Biosciences is a premier strategic partner to drug developers with liver-targeted therapies, such as for NASH, fibrosis, hepatocellular carcinoma (HCC) and metastatic cancers. We now offer this model in Canada as well as U.S.  See validation data below.

 
Oncology

For drug developers of cancer therapies, Woodland Biosciences also offers a wide range of cell-line based xenografts, including for lung, colon, pancreas, brain and breast cancers.  See examples below.  SBH Sciences is a key partner for in vitro studies and biomarkers.


Through alliances and partnerships with other CRO specialists in the Northeast Preclinical Network (NEPN.net), Woodland offers integrated discovery and preclinical services.  This network and the deep experience of drug development that it taps are especially valued by startups.  Please contact us to find out if we can help you.

Ask us about DMPK & safety pharmacology:

- Pharmacokinetics

​- Tolerability

- Necropsy services for pharmacodynamics

Services - Oncology:  Xenografts & Syngeneic Models


Woodland has a cell bank of over 300 human cancer cell lines in 22 indications.  We offer flank xenografts, orthotopic models, metastasis models and syngeneic models for immuno-oncology studies.   Alliances are in-progress to access select human primary tumors for PDX modeling.   Our strengths are in liver, pancreas, colon, brain, lung and breast cancer models.  Please ask us about adopting and validating your favorite academic model.  Inquiries for combination efficacy PK/PD are welcomed, with LC-MS bioanalytical services provided by NEPN partner NovaBioassays of Woburn, whose expertise includes protein and oligo analysis in addition to small molecules.

This is a standard two-hit model, with fibrosis being mild to moderate.  Woodland is working to exacerbate the disease in the male model with multiple liver insults.  Our model has been optimized to evaluate drug targets impinging on fat deposition, inflammation and directly on fibrosis and its reversal.  Scoring is available by pathologist or by digital analysis*.

Click here to jump to NASH service details below

​Woodland Biosciences Preclinical Services

Inflammation and the Tumor Microenvironment 


Woodland has begun to study the tumor cell - stroma interactions in the highly fibrotic cancers of the pancreas (desmoplastic) by looking at the secreted cytokines in pancreatic cancer (PDAC). 

Woodland's portfolio of syngeneic models for immuno-oncology studies:

Woodland has a large portfolio of regular flank xenografts:

  • >330 human cancer cell lines
  • 22 indications

Woodland Biosciences welcomes inquiries from startups using SBIR/STTR grant support to perform preclinical modeling.  Woodland has experience winning NIH/NCI grants as leading PI and in being a subcontractor to other projects.  We have ready templates for many standard documents (such as vertebrate animals), and can participate as editors for projects befitting Woodland's core capabilities.  For oncology and metabolic diseases, Woodland Biosciences may have sample material able to be analyzed for target expression (e.g. by RT-PCR or IHC) to be included in your submission as preliminary data.

Mouse Oncology Models


Woodland has >330 human cancer cell lines in 22 indications.  Please ask us for current pricing on:

- flank xenografts

​- syngeneic models

- orthotopic breast 4T1 model

- drug resistant cell lines

- metastasis models

​- HCC PDX modeling

- PK/PD screening


Growth curves shown for four cell lines:

  • H-1650 colon cancer 
  • CAPAN-1 pancreatic cancer 
  • A-549 lung cancer 
  • U-87MG brain cancer 

Woodland is partnering with a humanized mouse liver producer to establish initially a steatosis or fatty liver disease model in the human hepatocytes and then to continue to explore development of more traditional NASH with ballooning degeneration, lobular inflammation and fibrosis in the model.  A consortium of companies is being formed to aid in the development of this model, interested parties may inquire about participating and obtaining early access to a human NASH model.  See our press release later this year.


In addition to the longer term NASH studies, and based on our extensive experience in metabolic disease, Woodland is also offering Diet-Induced Obesity studies (DIO) for therapeutic intervention in the earlier stages of fat/lipids deposition in the liver and adipose tissues.  These studies may be acute or chronic and may be considered a precursor to the longer NASH studies if the drug target affects earlier targets in the process.


Northeast Preclinical Network - NEPN


NEPN Members


  • ​Affiliated partner companies

4T1 - breast
UNKC-6141 - pancreatic
(link)
B16F10 - melanoma
(link)
Renca - kidney
(link)
CT26 - colon
(link)
​Lewis Lung Carcinoma - lung

*Woodland Translational Research Canada, Inc. is hosted at the AAALAC-accredited facilities of CNBE-INRS in Laval, just west of Montreal, Quebec

Lewis Lung Carcinoma

The 3LL cell line is highly tumorigenic, but weakly metastatic, in C57black6, immune-competent mice.  3LL is the only reliable syngeneic lung cancer model available.  The model is somewhat prone to ulceration, requiring larger cohort sizes to account for animals culled early. Link here  for morphological characterization.


CT26 Colorectal Carcinoma

The mouse CT26 cell line grows aggressively and is one of the most widely used models for immuno-oncology studies.  It has been reported to have a KRAS mutation and also to be responsive to pro-inflammatory T cell activation.